SecBot SecBot
Biotech Drug Report Generated Jul 6, 2026

Kevzara

REGN·REGENERON PHARMACEUTICALS, INC.
NEUTRAL
Drug Impact Rating3/10
Trial phase
Approved
Time to market
Already approved and marketed since May 2017 (RA); latest label expansion (pJIA) approved June 2024
Why 3/10
Kevzara is already approved and marketed (RA since 2017, PMR since 2023, pJIA since 2024) with no pending PDUFA, pivotal readout, or regulatory decision in the next ~12 months. As a commercial-stage drug within a large, diversified biotech ($14.3B revenue in 2025), there is no hard binary catalyst ahead for this product alone.
Actionable Insight NEUTRAL

Kevzara is a steadily growing but non-blockbuster commercial drug for Regeneron. It contributes to Sanofi collaboration revenue but is dwarfed by Dupixent (~$17.8B global sales vs Kevzara's ~$600M). Investors should focus on Regeneron's bigger catalysts: the August 2026 PDUFA for garetosmab (FOP) and Dupixent label expansions, not Kevzara.

Price Chart

Loading chart...

Executive Summary

Kevzara (sarilumab) is an injectable IL-6 receptor blocker jointly developed and commercialized by Regeneron (REGN) and Sanofi (SNY). It was first FDA-approved in 2017 for rheumatoid arthritis, and has since expanded to polymyalgia rheumatica (2023) and polyarticular juvenile idiopathic arthritis (2024). Global sales reached roughly $600M in 2025, growing ~27% YoY, but the drug has fallen short of early $1B+ blockbuster expectations and faces entrenched competition from Roche's Actemra (tocilizumab). For Regeneron investors, Kevzara is a modest contributor, it is bundled into Sanofi collaboration revenues ($7.33B in 2025) alongside the far larger Dupixent ($17.8B global sales). There are no upcoming binary catalysts for Kevzara, making it a steady commercial product rather than a share-price driver.

How It Works

Kevzara is a lab-made antibody that blocks the interleukin-6 (IL-6) receptor. IL-6 is a protein that drives inflammation in the body. By sticking to and blocking the IL-6 receptor, Kevzara reduces inflammation, joint pain, and swelling in autoimmune conditions like rheumatoid arthritis.

Trial Status

Kevzara is FDA-approved across three indications: moderate-to-severe rheumatoid arthritis (RA, approved May 2017), polymyalgia rheumatica (PMR, approved Feb 2023 as the first and only biologic for this condition), and active polyarticular juvenile idiopathic arthritis (pJIA, approved June 2024). It is also approved in the EU. Earlier Phase 3 trials in COVID-19 failed to meet primary endpoints.

The Two-Sided Case

▲ Bull Case4
Steady double-digit sales growth: Kevzara global sales grew ~27% to ~$601M in 2025, per Sanofi-reported figures, driven by label expansions into PMR and pJIA.
First-to-market advantage in PMR: Kevzara is the first and only FDA-approved biologic for polymyalgia rheumatica, a condition with no prior biologic options, giving it a unique niche.
No near-term biosimilar threat: Patent protection for sarilumab extends into the mid-to-late 2030s, with no biosimilars currently in development or approaching market.
Contributes to Regeneron's growing Sanofi collaboration revenue, which increased 21% to $7.33B in 2025.
▼ Bear Case5
Far below early expectations: Initially forecast to reach $1B+ in peak sales, Kevzara generated only ~$600M globally in 2025, well short of blockbuster status.
Dominated by Actemra: Roche's tocilizumab (Actemra) is the established IL-6 inhibitor market leader with broader indications and longer commercial history, limiting Kevzara's market share in RA.
Highly diluted in Regeneron's portfolio: At ~$600M in global sales, Kevzara is roughly 3% the size of Dupixent ($17.8B), making it a non-material stock driver for REGN.
Failed COVID-19 trial: A high-profile Phase 3 program in COVID-19 patients failed to meet primary and key secondary endpoints, wasting development resources and marketing momentum.
Crowded RA market: Faces intense competition from multiple drug classes, JAK inhibitors (Xeljanz, Rinvoq), TNF blockers (Humira, Enbrel), and other biologics.

Upcoming Catalysts

  • No specific upcoming catalysts for Kevzara identified. The drug is fully approved with its latest label expansion (pJIA) completed in June 2024.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

REGENERON PHARMACEUTICALS, INC. 8-K REGN ·Originating report

Sources · 14

Hover a chip for the title
1 investor.regeneron.com2 drugs.com3 pharmacompass.com4 pharmashots.com5 hcplive.com6 sahmcapital.com7 stocktitan.net8 fiercepharma.com9 pharmaceutical-technology.com10 drugpatentwatch.com11 clinicaltrialsarena.com12 en.wikipedia.org13 sec.gov14 investor.regeneron.com